context: KX01 has been shown to be very effective against a broad range of cancers in both in vitro experiments and in animal cancer models.
answer_0: Naturally, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_1: Also, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_2: Locally, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_3: Interestingly, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_4: Typically, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_5: By doing this, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_6: Especially, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_7: Importantly, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_8: As a result, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.
answer_9: Initially, the compound has synergistic activities with most taxanes, including paclitaxel which is combined with KX01 in the current Phase Ia / IIb trial.